Pharmarise Holdings Dirección

Dirección controles de criterios 2/4

El CEO de Pharmarise Holdings' es Toshimichi Ohno, nombrado en Aug 2016, tiene una permanencia de 7.67 años. posee directamente un 29.45% de las acciones de la empresa, con un valor de ¥2.16B. La antigüedad media del equipo directivo y de la junta directiva es de 7.7 años y 7.7 años, respectivamente.

Información clave

Toshimichi Ohno

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	7.8yrs
Participación del CEO	29.5%
Permanencia media de la dirección	7.8yrs
Promedio de permanencia en la Junta Directiva	5.8yrs

Actualizaciones recientes de la dirección

Recent updates

Pharmarise Holdings' (TSE:2796) Shareholders Will Receive A Bigger Dividend Than Last Year

Mar 22

Pharmarise Holdings (TSE:2796) Is Paying Out A Larger Dividend Than Last Year

Mar 07

CEO

Toshimichi Ohno (72 yo)

7.8yrs

Permanencia

Mr. Toshimichi Ohno has been Chairman and Chief Executive Officer of Pharmarise Holdings Corporation since August 2016 and served as its President since June 1984. Mr. Ohno served as Senior Managing Direct...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Toshimichi Ohno	Chairman of the Board & CEO	7.8yrs	sin datos	29.45% ¥ 2.1b
Masayuki Akiyama	President	5.8yrs	sin datos	0.30% ¥ 21.6m
Keiko Matsuura	Senior MD & Director	14.8yrs	sin datos	0.36% ¥ 25.9m

7.8yrs

Permanencia media

69yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 2796 es experimentado (7.7 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Toshimichi Ohno	Chairman of the Board & CEO	40yrs	sin datos	29.45% ¥ 2.1b
Masayuki Akiyama	President	no data	sin datos	0.30% ¥ 21.6m
Keiko Matsuura	Senior MD & Director	14.8yrs	sin datos	0.36% ¥ 25.9m
Sayoko Ohno	Vice Chairman of the Board	34.9yrs	sin datos	3.71% ¥ 264.2m
Makoto Miura	Auditor	less than a year	sin datos	sin datos
Hiroshi Kanno	Director	3.8yrs	sin datos	0.064% ¥ 4.5m
Norio Watanabe	Independent External Director	8.8yrs	sin datos	0.024% ¥ 1.7m
Hiromu Tada	Independent External Director	7.8yrs	sin datos	sin datos
Yutaka Numata	Director	5.8yrs	sin datos	0.037% ¥ 2.6m
Ichijo Toda	Independent External Director	3.8yrs	sin datos	sin datos
Tsuneo Sonobe	Outside Audit & Supervisory Board Member	3.8yrs	sin datos	sin datos
Ai Aizawa	Director	less than a year	sin datos	sin datos

5.8yrs

Permanencia media

71yo

Promedio de edad

Junta con experiencia: La junta directiva de 2796 se considera experimentada (7.7 años de antigüedad promedio).

Pharmarise Holdings Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Pharmarise Holdings Corporation, Annual General Meeting, Aug 30, 2023

Less than half of directors are independent

Pharmarise Holdings Corporation, Annual General Meeting, Aug 25, 2022

Less than half of directors are independent

Recent updates

Upcoming dividend of JP¥20.00 per share

Pharmarise Holdings Corporation Revises Consolidated Earnings Guidance for the Fiscal Year Ending May 31, 2024

New minor risk - Financial position

Third quarter 2024 earnings released: JP¥8.36 loss per share (vs JP¥14.43 profit in 3Q 2023)

Pharmarise Holdings' (TSE:2796) Shareholders Will Receive A Bigger Dividend Than Last Year

Pharmarise Holdings (TSE:2796) Is Paying Out A Larger Dividend Than Last Year

Pharmarise Holdings Corporation to Report Q3, 2024 Results on Mar 25, 2024

Pharmarise Holdings Corporation (TSE:2796) entered into stock transfer agreement to acquire GOOD AID Inc. from Kotoshino Co., Ltd. and Yuta Hattori.

Pharmarise Holdings Corporation Provides Consolidated Earnings Guidance for the Fiscal Year Ending May 31, 2024

Second quarter 2024 earnings released: EPS: JP¥15.10 (vs JP¥4.15 loss in 2Q 2023)

New minor risk - Shareholder dilution

Pharmarise Holdings Corporation to Report Q2, 2024 Results on Dec 25, 2023

Pharmarise Holdings Corporation Provides Dividend Guidance for the Fiscal Year Ending May 31, 2024

Pharmarise Holdings Corporation Provides Dividend Guidance for the Fiscal Year Ending May 31, 2024

First quarter 2024 earnings released: EPS: JP¥13.05 (vs JP¥11.87 in 1Q 2023)

Full year 2023 earnings released: EPS: JP¥35.42 (vs JP¥47.90 in FY 2022)

Pharmarise Holdings Corporation to Report Q1, 2024 Results on Oct 11, 2023

Full year 2023 earnings released: EPS: JP¥35.42 (vs JP¥47.90 in FY 2022)

Pharmarise Holdings Corporation Announces Commemorative Dividend for the Fiscal Year Ending May 31, 2024

Pharmarise Holdings Corporation, Annual General Meeting, Aug 30, 2023

Pharmarise Holdings Corporation to Report Fiscal Year 2023 Results on Jul 11, 2023

Upcoming dividend of JP¥14.00 per share at 2.2% yield

Third quarter 2023 earnings released: EPS: JP¥14.43 (vs JP¥7.70 in 3Q 2022)

Pharmarise Holdings Corporation (TSE:2796) entered into basic agreement to acquire Two Dispensing Pharmacies in Mie Prefecture.

Pharmarise Holdings Corporation Provides Consolidated Earnings Guidance for the Full Year of Fiscal Year Ending May 31, 2023

Second quarter 2023 earnings released: JP¥4.15 loss per share (vs JP¥20.05 profit in 2Q 2022)

Pharmarise Holdings Corporation to Report Q2, 2023 Results on Dec 29, 2022

Less than half of directors are independent

First quarter 2023 earnings released: EPS: JP¥11.87 (vs JP¥6.78 in 1Q 2022)

Pharmarise Holdings Corporation Provides Consolidated Earnings Guidance for the Six Months and Full Year of Fiscal Year Ending May 31, 2023

Pharmarise Holdings Corporation to Report Q1, 2023 Results on Oct 13, 2022

Pharmarise Holdings Corporation Announces Cash Dividend for the Year Ended May 31, 2022, Payable on August 26, 2022; Provides Dividend Guidance for the Year Ending May 31, 2023

Pharmarise Holdings Corporation, Annual General Meeting, Aug 25, 2022

Full year 2022 earnings released: EPS: JP¥47.90 (vs JP¥45.78 in FY 2021)

Pharmarise Holdings Corporation (TSE:2796) agreed to acquire Two Dispensing Pharmacies.

Pharmarise Holdings Corporation to Report Fiscal Year 2022 Results on Jul 08, 2022

Upcoming dividend of JP¥14.00 per share

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: JP¥7.70 (vs JP¥1.40 loss in 3Q 2021)

Pharmarise Holdings Corporation to Report Q3, 2022 Results on Apr 12, 2022

Second quarter 2022 earnings: Revenues and EPS in line with analyst expectations

First quarter 2022 earnings released: EPS JP¥6.78 (vs JP¥5.93 loss in 1Q 2021)

Full year 2021 earnings released: EPS JP¥45.78 (vs JP¥61.03 in FY 2020)

Upcoming dividend of JP¥14.00 per share

Third quarter 2021 earnings released: JP¥1.40 loss per share (vs JP¥11.69 profit in 3Q 2020)

Pharmarise Holdings Corporation to Report Q3, 2021 Results on Apr 14, 2021

Second quarter 2021 earnings released: EPS JP¥19.54

Pharmarise Holdings Corporation to Report Q2, 2021 Results on Jan 14, 2021

Pharmarise Holdings Corporation to Report Q1, 2021 Results on Oct 15, 2020

CEO

Permanencia

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad